Rajab Amer, Pelletier Ronald P, Henry Mitchell L, Elkhammas Elmahdi A, Bumgardner Ginny L, Davies Elizabeth A, Orosz Charles G, Ferguson Ronald M
The Ohio State University Medical Center, Division of Surgery/Transplantation, Columbus, OH, USA.
Clin Transpl. 2005:111-7.
The goals and outcomes of immunosuppression in renal transplantation have changed significantly over the last 30 years. When graft survival rates were relatively low and acute rejection was a frequent occurrence in the early era of transplantation, the goal of immunosuppression was to improve survival and reduce the rate of acute rejection. Today, with excellent graft survival rates and a low incidence of acute rejection, the goal of immunosuppression has shifted toward not only eliminating acute rejection, but also toward reducing the side effects of medications, and maintaining long-term graft function by decreasing chronic nephropathy. Between September 1982-December 2004, 3,211 primary kidney transplant procedures were performed at The Ohio State University. We excluded from analysis all combined transplants as well as patients who were involved in clinical research protocols. Our immunosuppressive protocol changed substantially over this 24-year period, which can be divided into 5 eras in time. Each era is defined by a distinct immunosuppressive protocol that resulted in an incremental improvement in outcomes of patient and graft survival rates. In the present study, the outcomes of each era in patients with previous kidney transplant only are compared and future directions are discussed. The incidence of acute rejection episodes and graft survival from each era are compared and demonstrate the substantial improvement in results that have been achieved over the past 24 years.
在过去30年里,肾移植免疫抑制的目标和结果发生了显著变化。在移植早期,移植物存活率相对较低且急性排斥反应频繁发生,免疫抑制的目标是提高存活率并降低急性排斥反应的发生率。如今,移植物存活率良好且急性排斥反应发生率较低,免疫抑制的目标不仅转向消除急性排斥反应,还转向减少药物副作用,并通过降低慢性肾病来维持移植物的长期功能。1982年9月至2004年12月期间,俄亥俄州立大学进行了3211例原发性肾移植手术。我们在分析中排除了所有联合移植以及参与临床研究方案的患者。在这24年期间,我们的免疫抑制方案发生了重大变化,可分为5个时期。每个时期都由一种独特的免疫抑制方案定义,该方案使患者和移植物存活率的结果逐步得到改善。在本研究中,仅对既往有肾移植史的患者各时期的结果进行了比较,并讨论了未来的方向。比较了每个时期急性排斥反应发作的发生率和移植物存活率,结果表明在过去24年里取得了显著的改善。